2026 JADPRO Satellite Symposium: Empowering Oncology Teams in HER2 Testing: Applying the New NCCN Standards to Transform NSCLC Care-Symposium Presentation Video

Video Transcription

Video Summary

The symposium reviewed HER2 testing, treatment, and toxicity management in advanced non-small cell lung cancer (NSCLC). Speakers emphasized that HER2 mutations, protein overexpression, and gene amplification are distinct alterations and require different tests: next-generation sequencing (NGS) identifies mutations, immunohistochemistry (IHC) assesses overexpression, and FISH or NGS can detect amplification. Comprehensive testing should be considered for all eligible patients, regardless of smoking history or tumor type; tissue is preferred, while liquid biopsy can help identify mutations but cannot assess protein expression.<br /><br />For HER2-mutated NSCLC, treatment options include targeted tyrosine kinase inhibitors and trastuzumab deruxtecan (T-DXd). For tumors with HER2 IHC 3+ overexpression, T-DXd is an option in the subsequent-line setting. Treatment decisions depend on the specific alteration, prior therapy, disease burden, brain metastases, and toxicity risks. The speakers also noted that HER2 mutations may affect decisions about immunotherapy.<br /><br />T-DXd’s most urgent safety concern is interstitial lung disease (ILD) or pneumonitis. Clinicians should ask about new or worsening respiratory symptoms at every visit, investigate suspected cases promptly, and hold treatment while evaluating. Management depends on toxicity grade; grade 2 ILD requires permanent discontinuation. Other monitoring includes blood counts, liver tests, nausea, fatigue, and cardiac function.<br /><br />The panel highlighted ongoing gaps in biomarker testing, access to biopsies, and toxicity support, particularly in community settings. Advanced practice providers, nurses, pharmacists, navigators, and caregivers all contribute to timely testing, patient education, and safe care.

Meta Tag

Concept HER2

Concept Non-Small Cell Lung Cancer

Concept HER2 Mutation

Concept HER2-Targeted Therapy

Concept Trastuzumab Deruxtecan

Concept Interstitial Lung Disease

Keywords

HER2 testing

non-small cell lung cancer

NSCLC

next-generation sequencing

immunohistochemistry

FISH amplification

trastuzumab deruxtecan

HER2 mutations

interstitial lung disease

biomarker testing

HER2

Non-Small Cell Lung Cancer

HER2 Mutation

HER2-Targeted Therapy

Trastuzumab Deruxtecan

Interstitial Lung Disease